ACC 2026: Dulaglutide Promotes Coronary Plaque Stabilisation in Patients with T2D

Why It Matters

By directly improving plaque stability, dulaglutide may lower heart‑attack risk in diabetic patients, reinforcing its role in cardiovascular risk management and influencing future treatment guidelines.

Key Takeaways

• Dulaglutide reduced plaque lipid index over nine months
• Fibrous cap thickness increased significantly versus standard care
• Improved glucose time-in-range correlated with lipid reduction
• Study involved 39 T2D patients with intermediate stenoses
• Findings support GLP‑1RA cardiovascular protection beyond glycemic effects

Pulse Analysis

GLP‑1 receptor agonists have reshaped diabetes therapy, not only for glucose control but also for cardiovascular risk reduction. Landmark trials such as LEADER and REWIND demonstrated mortality benefits, yet the biological pathways remained partly speculative. The ACC 2026 presentation adds a crucial piece by visualising plaque composition changes with high‑resolution optical coherence tomography, offering a tangible mechanism that links drug action to heart‑attack prevention.

The prospective, randomised study enrolled 39 type‑2 diabetes patients whose coronary lesions fell between 25 % and 75 % stenosis. Over nine months, participants receiving once‑weekly dulaglutide showed a marked decline in lipid index—a surrogate for plaque fat content—and a measurable thickening of the fibrous cap, the thin layer whose rupture triggers acute events. Importantly, these structural improvements paralleled enhanced time‑in‑range glucose metrics, underscoring a possible synergistic effect where smoother glycaemic profiles amplify plaque stabilisation.

Clinicians should view dulaglutide as a dual‑action therapy that may transform vulnerable lesions into more resilient structures, potentially curbing myocardial infarction incidence among high‑risk diabetics. While the sample size is modest, the data justify larger, multicentre trials to confirm reproducibility and to assess long‑term outcomes. If validated, guideline committees could elevate GLP‑1RA recommendations from glycaemic adjuncts to cornerstone agents in cardiovascular prevention, expanding market demand and shaping future drug development pipelines.